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peritoneal carcinomatosis from 14% in the S-arm to 4% in the CRT+S-
arm (p<0.0001). There was also a small, but significant effect on 
hematogenous dissemination in favor of the CRT group (35 vs. 29%, 
p=0.025). LRRs occurred in 5% within the radiation field, in 2% in the 
margins of the radiation field, and in 6% outside the radiation field 
while in 1% the exact site in relation to the radiation field was 
unclear. Only 1% of patients had an isolated infield LRR after CRT+S. 
Conclusions: In patients with esophageal or junctional cancer, 
preoperative chemoradiotherapy improves locoregional control, 
reduces peritoneal carcinomatosis and has a favorable effect on 
hematogenous dissemination. Infield locoregional recurrences are 
rare.  
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Purpose/Objective: To evaluate the feasibility of high-dose 
stereotactic body radiation therapy (SBRT) in the treatment of 
unresectable liver metastases. 
Materials and Methods: Patients with one to three unresectable liver 
metastases with maximum individual tumour diameters less than 6cm, 
a Karnofsky Performance Status of at least 70, were enrolled and 
treated by SBRT on a phase II clinical trial. Dose prescription was 75Gy 
in 3 consecutive days.. SBRT was delivered using the volumetric 
modulated arc therapy (VMAT) by RapidArc technique, The primary 
end point was in–field local control. Secondary end points were 
toxicity, and survival. 
Results: Between February 2010 and September 2011, 61 patients 
with 76 lesions were treated. Among them, 21 (34.3%) had stable 
extrahepatic disease at study entry. The most frequent primary sites 
were colorectal(45.9%) and breast cancer(18%). 78.7% of patients had 
one lesion, 18.0% and 3.3% had 2 and 3 lesions, respectively. After a 
median of 12 months (range 2-26 months) in–field local response rate 
was 94%. Median OS rate was 19 months, actuarial survival at 12 
months was 83.5%. None of the patients suffered from grade 3 or 
higher acute toxicity. No radiation induced liver disease (RILD) was 
detected. One patient experienced G3 late toxicity at 6 months, due 
to chest wall pain. 
Conclusions: SBRT for unresectable liver metastases can be 
considered as an effective, safe, and noninvasive therapeutic option 
with excellent rates of local control and a low treatment related 
toxicity.  
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Purpose/Objective: During the ACCORD12 randomized trial, a specific 
evaluation of the clinical tumor response of the rectal cancer 
following neoadjuvant chemoradiotherapy (CRT) was performed 
before surgery. The correlation of this end point with patient 
characteristics and treatment outcomes is reported. 
Materials and Methods: Between 2005 and 2008 a randomized trial 
comparing 2 different regimens of CRT (cap45 : capecitabine + 45 
Gy/5w vs capox50 : capecitabine + 50 Gy/5w + oxaliplatine) included 
598 patients. A careful evaluation of the clinical response of the 
tumor was planned 5 weeks after the end of CRT just before surgery. 
Rectoscopy and digital rectal examination (DRE) was used to establish 
a specific score of clinical response adapted from the RECIST criteria : 
Clinical complete response : no visible or palpable tumor, supple 
rectal wall (CCR) ; partial response (PR), stable disease (ST), 
progressive disease (PROG). This score was correlated with patients 
characteristics, type of surgery, pathological response and 3-year 
clinical outcome. 
Results: Clinical response was evaluable in 475 patients. Score was as 
follow : CCR : 5%, PR : 62%, ST : 29%, PROG : 4%. There was a trend 
toward more CCR in the capox 50 arm (6,5 % vs 3,7 %). When analysed 
for the whole cohort of 475 patients, CCR was associated with early T 
stage (T2 : 11% vs T3-4 : 5%). CCR was associated with sphincter 
saving surgery, ypCR, CRM+, Disease Free Survival (table 1). 
Conclusions: CCR appears as a very important end point after 
neoadjuvant treatment of rectal cancer. It is correlated with 
increased pCR, negative CRM, 3 year DFS and it is probably influencing 
the chance of a sphincter saving procedure. Rectoscopy and DRE 
should be performed after neoadjuvant CRT to evaluate the tumor 
response and adapt the surgical technique.  
Reference : JP Gérard et al. Clinical outcome ACCORD12. 
10.1200/JCO.2012.42.8771 
 
 CCR (24 pts) % Part;Stable;Prog (451 pts) % 
Sph. Sav. Surg. 21 88 % 380 71 % 
ypCR 14 58 % 72 16 % 
CRM+ (≤1mm) 0 0 % 45 10 % 
3y DFS 91 % 70 % 
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Purpose/Objective: The increased use of high conformal radiation 
techniques with steep dose gradients requires a very precise definition 
of the clinical target volume (CTV). Although delineation guidelines 
are widely available, little is known about their correct 
implementation into daily practice. Within a national project we 
investigated the impact of central review on the quality of CTV 
delineation based on the guidelines as published by Roels et al 
(IJROBP 2006). 
Materials and Methods: Dedicated software (Aquilab, France) was 
installed at a central review facility and at each participating 
radiation oncology department. The CTV was uploaded on a secured 
server and centrally reviewed. In order to account for the variability 
in the time of inclusion between two patients in and between centres, 
we used a ranking system in which each 5 consecutive patients per 
centre were regarded as one category. This categorical patient order 
(cpatorder) was correlated with three volumetric parameters: kappa 
index (KI), volumetric ratio (RV) and commonly contoured volume 
(VCC). To compare the results of the volumetric parameters between 
the first ten patients and the others per centre a sensitive analysis 
was performed. A generalized linear model was used for normally 
distributed parameters (RV) and a regression logistic model for non-
normally distributed parameters (KI, VCC).  
Results: Between March 2010 and September 2012, 20 centres 
submitted 1255 rectal cancer cases, from which 1224 were included in 
the final analysis. A median of 64 patients were submitted per centre 
(range 6 -198). CTV was modified in 74.2% of the cases. Sensitive 
analysis demonstrated that there was a significant increase in RV and 
VCC between the first ten patients and the others (p<0.0005 resp. 
p<0.05) (Fig. 1). Statistical analysis did not show a sustained 
significant improvement in CTV delineation during the whole review 
period. When assessing the influence of the location of the primary 
tumour on CTV delineation, there was less consensus on delineation 
for mid seated lesions compared to low and high seated tumours. This 
might be explained by disagreement on which nodal volumes to 
include. 
 
 S162  2nd ESTRO Forum 2013	
 
  
 
Fig. 1: Least square means of RV by categorical patient order 
(corrected for CTV original and centre). 
 
Conclusions: Central review significantly improved the uniformity of 
the CTV delineation in the first ten rectal cancer patients submitted 
per centre. The high agreement on CTV delineations from the 
beginning of the review period and the fact that some centres 
submitted a low number of cases may explain the lack of a learning 
curve over the whole period. Further analysis of the data can highlight 
current ambiguities in the delineation guidelines and can help us in 
further improving these. 
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Purpose/Objective: Research on quality of cancer care (QoCC) during 
the last decade has demonstrated that the increase in knowledge on 
treatments with proven efficacy does not directly translate into 
optimal treatment delivery to patients. On the other hand, data 
describing the proportion of patients with rectal cancer (RC) who 
benefit of up-to-date evidence-based diagnostic-treatment procedures 
are still scarce in the literature. Aims of the present study are: 1) to 
describe the methods used for the selection of RC specific quality 
indicators (QI); 2) to analyse three QI concerning patients diagnosed 
with a new RC in Southern Switzerland and receiving neo-adjuvant 
radiation therapy (RT). 
Materials and Methods: QI have been developed in the context of a 
QoCC project as follows: seek and nomination of multidisciplinary RC 
Working Group, selection of QI on an evidence-based manner, choice 
of QI through a two-rounds Delphi-process and validation of final QI by 
an international Advisory Board (consensus ≥ 70%). Patients with RC 
incident from 2011 to 2012 were retrieved from the files of Ticino 
Cancer Registry. According to ICD-O-III tumour classification, 
epithelial tumours were included, but neuroendocrine, GIST, sarcoma, 
lymphoma. Additional information was extracted from the single 
pathology and RT records in both public and private hospitals. QI will 
be presented as proportion with the corresponding 95% confident 
intervals. The numerator and the denominator will be defined 
according to the definition of each QI. 
Results: We initially considered 51 rectum-specific QI, of which 15 
were RT-related. At the end of the whole process, 21 QI were finally 
validated (RT-related, N=9). Results of patients diagnosed with RC in 
2011-2012 will be presented for the following 3 RT-related QI: 1) 
proportion of patients with RC for which the request for the 
pathological examination includes the information of neo-adjuvant 
RT (in patients with RC undergoing neo-adjuvant RT and surgery); 2) 
proportion of patients with locally advanced RC undergoing neo-
adjuvant RT (in patients with locally advanced RC undergoing surgery; 
3) proportion of patients with RC and undergoing neo-adjuvant RT 
operated within 6-8 weeks after the end of neo-adjuvant RT (in 
patients with RC undergoing neo-adjuvant RT and surgery).  
Conclusions: QI are mandatory not only for clinicians, but also for 
stakeholders and patients. QI should be defined, developed and tested 
with scientific evidence-based rigor in a careful and transparent 
manner. The present QI study is based on expertise and active 
involvement of local health care providers and international experts 
representing all major disciplines (epidemiology, pathology, radiology, 
gastroenterology, surgery, radiation oncology, oncology, nuclear 
medicine), thus increasing quality, acceptance and translation of 
results into the daily clinical practice. 
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Purpose/Objective: To tailor treatment for locally advanced rectal 
cancer (LARC) an early accurate prediction of tumor response after 
preoperative chemoradiotherapy (CRT) is required. In literature, 
response prediction for LARC is mainly based on PET-imaging, but 
these studies are small and rarely validated. This study provides a 
prediction model based on a multicentric analysis of LARC response 
with clinical and sequential PET data of before and during treatment 
from three different institutes.  
Materials and Methods: In total, 112 patients from one institute were 
used to train the prediction model.The model was tested on 
respectively 78 and 28 patients from two different institutes. All LARC 
patients were prospectively accrued between 2007 and 2011 and 
received long-course radiotherapy (45-55 Gy) and concomitant 
chemotherapy. Two PETCT scans were made, pretreatment (day0) and 
halfway treatment (day 15). Tumors were semi-automatically 
contoured using a signal-to-background based threshold method. 
Extracted PET features of the two time points were SUVmean, SUVmax, 
metablic tumor volume (MTV) and maximal tumor diameter. Response 
indices between day0 and day 15 were calculated. They were 
analyzed together with age and gender of the patient and cT- and cN-
stage. The endpoint for prediction was pathologic complete response 
(pCR) defined as ypT0N0, based on pathology reviews of the resected 
specimen. Eleven patients who were also included in a wait-and-see 
study were considered to have pCR when they were recurrence free 
for at least 1 year. Significant predictors from a univariate Mann–
Whitney U test were included in a multivariate model based on 
logistic regression to predict tumor response. Performance of the 
model was expressed as a bootstrapped AUC (Area Under the Curve) of 
the Receiver Operating Characteristic (ROC).  
Results: The data distributions, number of missing values and pCR 
rates were similar between the institutes (Table). Based on the 
univariate analysis and outcome of the logistic regression, cT- and cN-
stage, maximal diameter at day15 and response index of SUVmax were 
selected as predictors. A nomogram was deducted from this model 
(Figure), resulting in performances of 0.78 for the training dataset and 
0.69 and 0.64 for the smaller validation datasets.  
 
 Conclusions: Sequential PET-imaging has predictive power for 
response after chemoradiotherapy in LARC patients. Application of the 
developed model in other institutes is less accurate, but still useful 
for tailored decision making. When patients are assigned to risk groups 
for an uncomplete response, high risk patients may be candidates for 
radiotherapy boost and adjuvant chemotherapy strategies, while the 
low risk patients may be followed-up with a wait-and-see policy, 
